IDEAYA Biosciences Announces Promising Phase 1 Clinical Trial Results for IDE849 in SCLC and Other DLL3 Upregulated Tumors at WCLC 2025
IDEAYA Biosciences, in collaboration with Hengrui Pharma, announced promising Phase 1 clinical trial results for IDE849, a DLL3-targeting antibody drug conjugate, at the IASLC 2025 World Conference on Lung Cancer. The trial involved 100 patients and showed a manageable safety profile with a median progression-free survival of 6.7 months at doses of 2.4 mg/kg or higher. Further updates will be available on IDEAYA’s Investor Relations page.
IDEAYA Biosciences, Inc., a precision medicine oncology company, in collaboration with Hengrui Pharma, has announced the presentation of initial data from a Phase 1 clinical trial of IDE849 (SHR-4849) at the IASLC 2025 World Conference on Lung Cancer in Barcelona, Spain. IDE849 is a potential first-in-class delta-like ligand 3 (DLL3)-targeting Topoisomerase-1 (TOP1) antibody drug conjugate (ADC) aimed at treating small cell lung cancer (SCLC) and neuroendocrine carcinomas (NECs). The trial involved 100 patients receiving doses ranging from 0.8 mg/kg to 4.2 mg/kg every three weeks. Results indicated a manageable safety profile, with a median progression-free survival of 6.7 months across all lines of SCLC at doses of 2.4 mg/kg or higher. Further updates and the oral presentation will be accessible on the Investor Relations page of IDEAYA’s corporate website. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF66881) on September 07, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
